More Videos
- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Options Trading: One Airline Stock May Zoom
- Hell Freezes: Piper Downgrades Apple
- Is Merck A Drug Bellwether?
- Global Interest Rates
- My ESP: Sports Clubs Take On Airline Pricing
- Busch: Spanning the Rate Cut Globe
- Adidas' Rival Brings Free Holiday Beer — To Adidas
- How to Manage a Job Layoff (Part 1)
- Marisa Miller's Weapon: Brain Behind the Body
- Bernanke: 'More Needs To Be Done' on Foreclosures
- Bernanke's Speech on Housing and Foreclosures
- With Saturn, G.M. Failed a Makeover
- Toll Loss Narrows, but Warns on Revenue
- Factory Orders Drop More Than Expected in October
- Treasurys Gain on Global Recession Fears
- Happy Holidays? Economy Goes From Bad to Worse
- Where the Layoffs Are—Is Your Firm on the List?
- Viacom to Cut 850 Jobs, Freeze Some Raises
Text Size 
I've blogged many times about the embargoes imposed by scientific groups and medical journals. If a media outlet breaks one -- something I have not done -- they risk losing the "privilege" of receiving the info ahead of time. And there's been a recent example of a prominent doctor who spoke too soon and has been barred for a while from publishing and reviewing studies in a peer-reviewed journal. Well, now at least one organization may take the enforcement a step further.
Reuters broke the story that three research analysts -- one at Merrill Lynch, another at Natexis Bleichroeder and the third at JPMorgan -- issued reports earlier this week with embargoed data from the upcoming American Academy of Neurology conference.
Two of the research notes to clients were about an experimental Alzheimer's drug from Baxter [BAX
Loading...
()
]. And the other note focused on the MS drug Tysabri from BIIB [BIIB
Loading...
()
] and ELN [ELN
Loading...
()
].
Reuters says the JPM and Natexis reports were retracted or recalled and that Merrill declined to comment.
But a spokesperson for the AAN says the recall or retraction may not be sufficient and that the organization could possibly try to take some kind of legal action. Here's their statement:
“The American Academy of Neurology is disappointed that representatives of financial organizations have deliberately violated the Academy’s embargo policy. The violation has been referred to the Academy’s General Counsel who is currently exploring all options available to the Academy.”
The embargo issue keeps cropping up for the organizations and journals that are trying to protect their "scientific integrity" and potentially headline-making content while servicing the companies that often sponsor the research (and the conferences) and in which Wall Street has a vested interest.
It will once again be put to the test over the next couple of months when the most widely-followed conference by doctors, scientists, investors, reporters and analysts--the American Society of Clinical Oncology annual meeting--employs a new policy this year with some of its data to try to satisfy everyone.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes